These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 31217189)

  • 1. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD
    He X; Zhu Y; Lin YC; Li M; Du J; Dong H; Sun J; Zhu L; Wang H; Ding Z; Zhang L; Zhang L; Zhao D; Wang Z; Wu H; Zhang H; Jiang W; Xu Y; Jin J; Shen Y; Perry J; Zhao X; Zhang B; Liu S; Xue SL; Shen B; Chen CW; Chen J; Khaled S; Kuo YH; Marcucci G; Luo Y; Li L
    Blood; 2019 Aug; 134(6):548-560. PubMed ID: 31217189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
    Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.
    Zhu Y; He X; Lin YC; Dong H; Zhang L; Chen X; Wang Z; Shen Y; Li M; Wang H; Sun J; Nguyen LX; Zhang H; Jiang W; Yang Y; Chen J; Müschen M; Chen CW; Konopleva MY; Sun W; Jin J; Carlesso N; Marcucci G; Luo Y; Li L
    Blood; 2019 Oct; 134(15):1257-1268. PubMed ID: 31395602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
    Ma HS; Greenblatt SM; Shirley CM; Duffield AS; Bruner JK; Li L; Nguyen B; Jung E; Aplan PD; Ghiaur G; Jones RJ; Small D
    Blood; 2016 Jun; 127(23):2867-78. PubMed ID: 27103744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B; Zhao Y; Wang X; Gong P; Ge W
    Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD
    Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J
    Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
    Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.
    Heydt Q; Larrue C; Saland E; Bertoli S; Sarry JE; Besson A; Manenti S; Joffre C; Mansat-De Mas V
    Oncogene; 2018 Feb; 37(6):787-797. PubMed ID: 29059168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.
    Ma H; Nguyen B; Li L; Greenblatt S; Williams A; Zhao M; Levis M; Rudek M; Duffield A; Small D
    Blood; 2014 Mar; 123(10):1525-34. PubMed ID: 24408321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.
    Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B
    Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 14. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
    Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
    Larrue C; Saland E; Boutzen H; Vergez F; David M; Joffre C; Hospital MA; Tamburini J; Delabesse E; Manenti S; Sarry JE; Récher C
    Blood; 2016 Feb; 127(7):882-92. PubMed ID: 26286850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification.
    Tian T; Li J; Li Y; Lu YX; Tang YL; Wang H; Zheng F; Shi D; Long Q; Chen M; Garcia-Manero G; Hu Y; Qin L; Deng W
    Theranostics; 2019; 9(13):3768-3779. PubMed ID: 31281512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
    Wu M; Li L; Hamaker M; Small D; Duffield AS
    Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
    J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
    Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
    Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
    Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.